Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

Overview

About this study

This screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloid leukemia will determine which sub-study, within this protocol, a participant will be assigned to evaluate investigational therapies or combinations with the ultimate goal of advancing new targeted therapies for approval. The study also includes a marker negative sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- Adults, age 60 years or older at the time of diagnosis unless in a specific known
cytogenetic and genomic group for which treatment in Group A or B is allowed by the
sub-study where age 18 and older is allowed. Patients < 60 years old who are screened
but do not fall within the cytogenetic and genomic open sub-studies would still be
followed on the Master Protocol and not considered screen fails.

- Subjects must be able to understand and provide written informed consent

- Cohort Inclusion Criteria - Group A: Subjects must have previously untreated acute
myeloid leukemia (AML) according to the WHO classification with no prior treatment
other than hydroxyurea. Subjects with blasts % in bone marrow of 10% to 19% or blasts
in blood of 10% to 19% will be allowed to enroll to this group. For previously
untreated subjects with ≥ 20% blasts in bone marrow or blood only: Prior therapy for
myelodysplastic syndrome (MDS), myeloproliferative syndromes (MPD), or aplastic anemia
is permitted but not with hypomethylating agents.

- Cohort Inclusion Criteria - Group B: Subjects must have relapsed or refractory AML
according to the WHO classification. For study purposes, refractory AML is defined as
failure to ever achieve CR or recurrence of AML within 6 months of achieving CR;
relapsed AML is defined as all others with disease after prior remission. For select
genomic aberrations specified in the studies, patients ≥ 18 years of age may be
allowed to enroll in this portion of the study.

Exclusion Criteria:

- Isolated myeloid sarcoma (meaning, patients must have blood or marrow involvement with
AML or involved with 10% to 19% blasts to enter the study)

- Acute promyelocytic leukemia

- Symptomatic central nervous system (CNS) involvement by AML

- Signs of leukostasis requiring urgent therapy

- Disseminated intravascular coagulopathy with active bleeding or signs of thrombosis

- Patients with psychological, familial, social, or geographic factors that otherwise
preclude them from giving informed consent, following the protocol, or potentially
hamper compliance with study treatment and follow-up

- Any other significant medical condition, including psychiatric illness or laboratory
abnormality, that would preclude the patient participating in the trial or would
confound the interpretation of the results of the trial

Eligibility last updated 6/3/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

James Foran, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

-

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Lisa Sproat, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

Jacksonville, Fla.

Mayo Clinic principal investigator

James Foran, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

More information

Publications

Publications are currently not available
.
CLS-20490731

Mayo Clinic Footer